Get the Daily Brief
Latest Biotech News
J. Craig Venter co‑founds Diploid Genomics to marry AI and sequencing
The J. Craig Venter Institute spun out Diploid Genomics with seed investment from Healthier Capital to build an AI‑driven genomics analytics and diagnostics platform. Founders include Craig...
Mount Sinai’s macrophage‑targeted CAR T reprograms solid tumors in mice
Researchers at the Icahn School of Medicine at Mount Sinai reported preclinical data showing IL‑12‑producing CAR T cells that target tumor‑associated macrophages (TAMs) remodel the tumor...
FDA advances MRD guidance — new path to speed multiple myeloma trials
Regulators signaled support for measurable residual disease (MRD) and complete response as potential accelerated approval endpoints in multiple myeloma, publishing draft guidance and a related...
Nanopore cytogenetics hits clinical pilots in Italy
Swiss company 4bases launched clinical pilot studies in two Italian hospitals to validate a nanopore sequencing‑based cytogenetics workflow called KaryoSolver for real‑time detection of...
NVIDIA–Lilly $1B AI lab: drug discovery scales up
NVIDIA and Eli Lilly announced a joint $1 billion initiative to build an AI-powered drug discovery laboratory in the San Francisco Bay Area. The partnership will combine NVIDIA’s compute and...
Bristol Myers bets on Janux – $50M upfront, $850M possible
Bristol Myers Squibb struck a collaboration and exclusive license with Janux Therapeutics to develop tumor‑activated T‑cell engager therapies, paying roughly $50 million up front and potential...
Corxel raises $287M: oral GLP‑1 clinical push
Corxel Pharmaceuticals closed a $287 million financing to advance global development of an oral GLP‑1 candidate licensed from China‑based Vincentage. The company said proceeds will fund phase 2/3...
BioMarin vets form Mendra: $82M to buy rare‑disease assets
Mendra, a new rare‑disease company founded by former BioMarin executives, raised $82 million in a Series A to acquire, develop and commercialize under‑resourced rare disease programs. The...
Corcept’s relacorilant: phase 3 survival win lifts approval odds
Corcept Therapeutics reported phase 3 data showing that relacorilant, an oral selective glucocorticoid receptor antagonist, reduced the risk of death by 35% in platinum‑resistant ovarian cancer...
FDA opens MRD path: draft guidance for multiple myeloma
The U.S. Food and Drug Administration released a draft guidance clarifying that measurable residual disease (MRD) negativity and complete response could support accelerated approval pathways in...
Guardant360 CDx cleared: liquid biopsy wins new companion role
The FDA approved Guardant Health’s Guardant360 CDx blood test as a companion diagnostic for Pfizer’s encorafenib (Braftovi) combination regimen in BRAF V600E‑mutant metastatic colorectal cancer,...
Venter launches Diploid Genomics: AI meets clinical‑grade sequencing
Genomics pioneer J. Craig Venter and co‑founders launched Diploid Genomics with seed funding from Healthier Capital to build an AI‑driven genomics analytics platform for discovery and diagnostics....
Robotics milestone: integrated automation for cell and gene therapy
Cellular Origins and Fresenius Kabi announced completion of the first integration phase of their collaboration to automate cell and gene therapy (CGT) manufacturing. The teams integrated Fresenius...
NIH ends fetal tissue research: policy shift draws criticism
The National Institutes of Health announced an end to support for research using human fetal tissue, a move observers described as politically driven rather than science‑based. The decision...
Nvidia-Lilly pact: $1B AI lab to power drug discovery
Nvidia and Eli Lilly announced a $1 billion collaboration to build an AI-powered drug discovery laboratory in the San Francisco Bay Area. The partnership combines Nvidia’s AI infrastructure and...
Corxel raises $287M — funds oral GLP‑1 global development
Corxel Pharmaceuticals closed up to $287 million to advance global development of an oral GLP‑1 candidate licensed from Vincentage, the company said. The financing will bankroll phase 2/3 studies...
Mendra raises $82M — AI-guided rare disease roll-up
Mendra, founded by former BioMarin executives, secured $82 million in Series A financing to acquire and develop underutilized rare-disease assets and accelerate development with AI-enabled...
Bristol Myers bets $50M on Janux’s masked T‑cell engagers
Bristol Myers Squibb signed a collaboration and exclusive license with Janux Therapeutics, committing $50 million up front for access to Janux’s tumor‑activated T‑cell engager platform and a lead...
Guardant360 CDx wins FDA nod for Pfizer BRAF colorectal combo
The FDA approved Guardant Health’s Guardant360 CDx as a companion diagnostic for identifying BRAF V600E–mutant metastatic colorectal cancer patients eligible for Pfizer’s encorafenib (Braftovi)...
Corcept’s relacorilant extends survival — ovarian cancer win
Corcept Therapeutics reported that relacorilant, an oral selective glucocorticoid receptor antagonist, reduced risk of death by 35% in a phase 3 trial for platinum‑resistant ovarian cancer and met...